Innovative Nanobody Targeting ITGA3 and ITGB1 for Cancer Therapy

VHH-P776 is a fully humanized nanobody designed to target integrin subunit alpha 3 (ITGA3) and integrin subunit beta 1 (ITGB1), two key components of the alpha3beta1 integrin complex implicated in cancer progression and metastasis. Currently in Biological Testing, VHH-P776 harnesses the specificity and unique binding capabilities of nanobodies to selectively modulate the function of these integrins. This targeted approach demonstrates significant therapeutic potential for the treatment of cancer, offering a new strategy to inhibit tumor invasion and dissemination by focusing on critical adhesion molecules involved in tumor cell migration.

Licensing Opportunity

VHH-P776 is available for out-licensing and collaborative development. We invite partners interested in advancing a next-generation nanobody therapeutic targeting ITGA3 and ITGB1 for cancer to contact us for further discussion.

Development Phase

Modality

VHH-P776 is a single-domain antibody, also known as a nanobody, engineered to specifically bind the alpha3beta1 integrin complex on human cells. The nanobody format features a compact structure, consisting solely of the variable domain of heavy chain antibodies, which endows it with exceptional stability, solubility, and tissue penetration compared to conventional antibodies. These properties are particularly advantageous in cancer therapy, enabling VHH-P776 to efficiently access tumor microenvironments and interact with cell surface targets such as ITGA3 and ITGB1. Its smaller molecular size also facilitates alternative administration routes and rapid systemic distribution, expanding its therapeutic reach.

Target

ITGA3 and ITGB1 are integral membrane proteins that combine to form the heterodimeric alpha3beta1 integrin complex, mediating cell adhesion to the extracellular matrix and regulating diverse cellular processes including migration, invasion, and survival. ITGA3 and ITGB1 are primarily expressed in epithelial and endothelial tissues, where they play pivotal roles in tissue architecture and repair. In the context of cancer, aberrant expression or activation of ITGA3 and ITGB1 has been associated with enhanced tumor invasiveness and metastatic spread. Targeting ITGA3 and ITGB1 offers a promising approach to disrupt the pathological signaling pathways driving cancer progression. The development of VHH-P776 as a specific binder to ITGA3 and ITGB1 represents a strategic asset for cancer therapeutics, leveraging the accessibility of these cell surface molecules to achieve selective anti-tumor effects.

Mechanism of Action

VHH-P776 functions as a signal transduction modulator by specifically binding to the alpha3beta1 integrin complex, comprising ITGA3 and ITGB1, thereby interfering with its role in mediating cellular adhesion, migration, and downstream signaling events. By inhibiting the interaction of tumor cells with their microenvironment, VHH-P776 may reduce cancer cell motility and invasiveness, limiting metastatic potential. The nanobody's precise targeting allows for effective disruption of integrin-mediated pathways without widespread off-target effects. Additionally, the VHH format of VHH-P776 offers potential for further functionalization, such as conjugation with payloads (e.g., in antibody drug conjugates) or bispecific constructs, broadening therapeutic applications in oncology.

Cancer

Cancer encompasses a diverse set of diseases characterized by the uncontrolled growth, invasion, and spread of abnormal cells. As a global health challenge, cancer is one of the leading causes of morbidity and mortality worldwide. Current mainstays of treatment include surgery, radiotherapy, chemotherapy, and a variety of targeted therapies and immunotherapies, all aiming to reduce tumor burden and improve survival outcomes. Despite considerable advancements, significant limitations remain, such as toxicity, resistance development, and inadequate targeting of metastatic disease. Many patients with advanced or aggressive cancers continue to face poor prognoses and limited therapeutic options. There is a clear unmet need for novel, highly specific modalities capable of overcoming resistance and effectively controlling tumor progression. VHH-P776, by selectively targeting ITGA3 and ITGB1, holds promise in addressing these therapeutic gaps, particularly by inhibiting mechanisms critical for tumor spread and offering compatibility with advanced therapeutic platforms.